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Abstract Data on the prevalence of congenital heart
defects (CHD) in neuroblastoma patients are inconsistent.
If CHD are more common in neuroblastoma patients than
in the general population, cardiac screening might be
warranted. In this study we used echocardiography to
determine the prevalence of CHD in a single centre cohort
of surviving neuroblastoma patients. In addition, we
performed a systematic review of the literature. Echocardi-
ography was performed in 119 of 133 patients (89.5%).
Only two patients (1.7%) had CHD. The prevalence of
CHD was not significantly different from a previously
published control group of 192 leukaemia patients exam-
ined by echocardiography (P=0.49). Literature search
revealed 17 studies, showing prevalence rates of CHD in
neuroblastoma patients ranging from 0 to 20%. Prevalence
was less than 3.6% in the majority of studies. Most studies
lacked information on validity. We conclude that current
evidence does not support standard cardiac screening in all
patients with neuroblastoma.
Keywords Neuroblastoma.Congenitalheartdefects.
Echocardiography.Association.Screening.Neuralcrest
Introduction
Neuroblastoma is an embryonal cancer of the postgangli-
onic sympathetic nervous system, which mostly arises in
the adrenal gland. It is the most common extracranial solid
tumour in children, comprising 8% to 10% of all childhood
cancers. The incidence is nearly one per 10,000 children
under the age of 15 years [3].
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Utrecht, The NetherlandsSeveral case reports have been published of patients with
coexisting neuroblastoma and congenital heart defects
(CHD) [1, 8, 10, 17, 28]. Some studies of patients with
neuroblastoma suggest a higher prevalence of CHD in
neuroblastoma patients than in the general population [5, 6,
9, 11, 18], however, others did not find an association
between neuroblastoma and CHD [2, 20–25]. An associa-
tion between neuroblastoma and CHD is considered to be
plausible as neuroblastoma originates from embryonal
neural crest-derived cells [3], and neural crest-derived cells
are essential in cardiogenesis as well [14]. Neural crest cells
play an important role in the septation of the outflow tract
of the heart and in the formation of the conotruncal part of
the ventricular septum [14]. Abnormal development or
migration of neural crest cells, possibly due to an
underlying genetic defect, has been postulated as a
mechanism that could contribute to both conditions [1, 11,
13, 28]. Indeed, neural crest-derived CHD have been
reported to be more frequent in neuroblastoma patients
than is expected when considering the normal distribution
of subtypes of CHD [11, 13].
An association between neuroblastoma and CHD might
have clinical consequences: if neuroblastoma patients have
a higher risk of CHD, cardiac screening might be indicated
for all neuroblastoma patients. Early detection of CHD
could be important for the patient, in terms of bacterial
endocarditis prophylaxis, choice of anti-cancer treatment
and possible need for treatment of the CHD.
To assess the prevalence of CHD in neuroblastoma
patients we conducted an echocardiographic study in a
large single centre cohort of consecutive neuroblastoma
patients. In addition, we systematically searched and
critically appraised the literature to evaluate the existing
evidence regarding the prevalence of CHD in neuroblasto-
ma patients.
Materials and methods
Patients
The study group consisted of all patients diagnosed with
neuroblastoma or ganglioneuroblastoma at the Emma
Children’s Hospital, Academic Medical Centre (AMC),
the Netherlands, between June 1966 and September 2006,
who were eligible for echocardiography, i.e. all living
patients (surviving patients and patients more recently
diagnosed with neuroblastoma). The Emma Children’s
Hospital-AMC is one of the five paediatric oncology
centres in the Netherlands with a constant referral region.
To minimise referral bias, we did not include patients who
had been referred from another Dutch paediatric oncology
centre to the Emma Children’s Hospital-AMC for
specialised cancer treatment. Patients referred from other
countries were also excluded. We placed special emphasis
on making the cohort as complete as possible to minimise
Neuroblastoma patients with 
(ganglio)neuroblastoma diagnosed in 
AMC 1966-2006 (n = 385) 
Patients originally from AMC (n = 318) 
Patients eligible for echocardiography     
(n = 133) 
Patients referred from other 
centers (n = 67) 
Patients deceased at time of 
study (n = 185) 
No accurate echocardiography performed 
previously (n = 116)  Patients lost to follow up    
(n = 12) 
Moved abroad: n = 3 
No consent: n = 7 
Not traceable: n = 2 
Echocardiography newly performed        
(n = 104) 
Patients with accurate echocardiography 
(n = 119) 
Echocardiography of 
insufficient quality (n = 2) 
Accurate echocardiography 
performed previously (n = 17) 
Fig. 1 Flow chart of inclusion
and exclusion of patients
1082 Eur J Pediatr (2009) 168:1081–1090bias by selective follow-up. Patients who were deceased
were not included in the echocardiography study; however,
we reviewed medical charts of these patients to look for
CHD.
Methods
One experienced paediatric cardiologist (JL) reviewed and
performed all echocardiograms at the same laboratory in the
AMC. First, we retrospectively analysed the echocardio-
graphic images of patients who underwent echocardiogra-
phy in the past before the start of this study. If the images
were extensive enough to diagnose or exclude CHD, we
used these in this study. If the images were not sufficient, or
if echocardiographic data were not available, patients were
invited to participate in this study. In the vast majority of
patients, echocardiography was prospectively performed
especially for this study. In those patients in whom accurate
echocardiography could not be obtained we reviewed
medical charts for evidence of CHD. Standard diagnostic
definitions were used for CHD. Patent foramen ovale (PFO)
at any age and atrial septal defect (ASD) or patent ductus
arteriosus (PDA) at less than 2 months of age were
regarded to be normal stages of cardiovascular development
and therefore where not considered to be CHD.
Neuroblastoma staging was performed according to the
International Neuroblastoma Staging System (INSS) criteria
[4]. In patients who had been diagnosed with neuroblasto-
ma before the introduction of the INSS, we converted the
staging system that had been used into the INSS. MYCN
oncogene amplification was analysed by southern blot
analysis of tumour cells.
Data analysis
We compared the prevalence of CHD in our cohort of
neuroblastoma patients who had echocardiography with the
prevalence of CHD in the acute lymphoblastic leukaemia
(ALL) cohort as presented by George et al. [11]. This
cohort consisted of 192 children diagnosed with ALL in
one hospital in Boston, USA, between 1990 and 2000, who
all have had echocardiography screening. We also com-
pared the prevalence of CHD in our cohort to data from
EUROCAT Northern Netherlands (1981–2005), a network
for the registration of congenital anomalies (European
Registration Of Congenital Anomalies) [7]. Children with
congenital anomalies are registered in EUROCAT since
1981, after report by midwives, general practitioners and
specialists. We estimated prevalence of CHD in patients as
a proportion. Significance of our findings was determined
by use of two-tailed P-values calculated by comparing the
proportion of patients with CHD in our cohort to the
proportion of patients with CHD in the control group
(Fisher exact test).
Results
Between June 1966 and September 2006, 385 patients had
been diagnosed with (ganglio)neuroblastoma at the Emma
Table 1 Characteristics of the study group (n=119)
Male (%) 51 (42.9)
Median age at diagnosis of neuroblastoma in years
(range)
0.8 (0.0–10.5)
Tumour stage (INSS) I–III (%) 74 (62.2)
IV (%) 45 (37.8)
Tumour MYCN amplification Yes (%) 4 (3.4)
Unknown (%) 49 (41.2)
Median age at echocardiography in years (range) 15.7 (0.8–41.4)
Potentially relevant publications 
identified and screened for retrieval 
(n = 515) 
Publications retrieved for more 
detailed evaluation (n = 78) 
Publications included (n = 17) 
Excluded (n = 437) 
 Not meeting inclusion criteria 
Excluded (n = 61) due to: 
 Case report: 37 
 No neuroblastoma: 8 
 No CHD: 12 
 Not about prevalence: 2 
Data reported elsewhere: 2
Fig. 2 Publications identified
for study and exclusions
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cluded from this study because they had been referred from
other centres. One hundred eighty-five patients had de-
ceased by the time of the start of this study. The study
group therefore consisted of 133 living patients. Inclusion
and exclusion of patients is illustrated in Fig. 1.
In 34 of 133 patients an echocardiogram had been
performed in the past. The images of 17 of 34 patients were
extensive enough for confirming or ruling out the presence
of CHD and therefore were analysed retrospectively. The
17 patients with inaccurate echocardiography as well as 99
patients without echocardiography were approached to
undergo cardiac evaluation. We obtained echocardiography
in 104 of these 116 patients. In the remaining 12 patients,
echocardiography could not be performed: three patients
had moved abroad, two patients were untraceable and seven
patients refused to undergo echocardiography. Two addi-
tional patients, children aged 12 and 24 months, were
Table 2 Description of selected articles
Study Miller et al. [21] Miller et al. [20] Berry et al. [2] De la Monte et al. [6]
Country and time period USA, different time
periods within
1941–1964
USA, 1960–1966 UK, time period nm USA, 1889–1982
Design and setting Multicentre retrospective
patient series
Multicentre
(all USA) retrospective
cohort study
Single centre retrospective
patient series
Single centre retrospective
cohort study
Patients and methods
NB patients Patients (<15 years)
with NB listed in the
diagnostic files of the
hospitals and
National Cooperative
Leukaemia Survey
(n=nm)
Patients (<15 years) who died of
NB (n=2,093)
Patients with NB (n=nm) Patients with NB listed in
autopsy files with tumour
present at
autopsy (n=63)
a
N of patients analysed
(%)
504 (% unclear) 2,093 (100) 144 (% unclear) 63 (100)
NB stage nm nm nm nm
Control patients –– – A. Patients from remaining
autopsy population minus
peripheral neuroblastic
tumours
(n=43,149)
B. Patients with malignant
melanoma or central
neuroblastic
tumour in same autopsy
population (n=135)
Method of review of
cardiac status
Review of medical charts Review of death certificates Review of medical records Review of autopsy files
(in addition all available
fixed heart
specimens and post-
mortem coronary
angiograms of CHD were
studied)
Results
N of patients with CHD
(%)
7 (1.4) 6 (0.3) 2 (1.4) 7 (11.1)
N of controls with CHD
(%)
–– – A. 2,081 (4.8)
B. 0 (0)
Significance –– – nm
Nakissa et al. [23] Neglia et al. [25] Mann et al. [16] Mili et al. [19] Foulkes et al. [9] NB neuroblastoma, CHD congenital heart defects, nm not mentioned
aNeuroblastoma was detected incidentally at autopsy in all patients with CHD
bIn six cases neuroblastoma was detected incidentally, of which three cases during evaluation of CHD
cIn all patients with CHD neuroblastoma was detected in a screening programme using urine samples
dOdds ratio for neuroblastoma risk in patients with CHD
1084 Eur J Pediatr (2009) 168:1081–1090eventually excluded because echocardiography of sufficient
quality could not be obtained due to unrest during the
performance of the echocardiogram. Altogether, accurate
echocardiography was available in 119 of the 133 eligible
patients (89.5%), of which 102 were obtained prospectively
and 17 retrospectively. Characteristics of these 119 patients
are given in Table 1.
Two of 119 patients with echocardiography had CHD
(1.7%, 95% CI 0.20–5.94). One patient was a 19-year-old
male with a ventricular septal defect (VSD) at birth, which
had spontaneously closed when he was 1 year old. In the
other patient, a 19-year-old woman, echocardiography
revealed a persistent left superior vena cava. Both patients
were asymptomatic. No CHD was detected in any of the
remaining 117 patients. In one patient, a 3-year-old boy
with psychomotor retardation, hypertrophic cardiomyopa-
thy was present, which had already been diagnosed before
the start of this study and pre-existed before treatment for
the neuroblastoma. The cause of the cardiomyopathy is
unknown. In the control group of ALL patients, seven of
192 (3.6%) patients were reported to have CHD [11]. The
proportion of CHD in our cohort of surviving neuroblasto-
Table 2 (continued)
Nakissa et al. [23] Neglia et al. [25] Mann et al. [16] Mili et al. [19] Foulkes et al. [9]
USA, 1965–1980 USA, 1969–nm England, time period nm USA, 1983–1988 Canada, 1977–1993
Single centre
retrospective
patient series
Multicentre retrospective
patient series
Multicentre retrospective
patient series
Multicentre (cancer registry)
retrospective cohort study
Single centre retrospective
cohort study
Patients and methods
Patients (0–12 years)
with NB visiting
the centre within
time period
(n=nm)
Patients with NB newly
diagnosed or seen
in survey region
and born in survey
region (n=97)
Patients newly diagnosed
with NB (n=nm)
Incident cases of NB
registered in cancer
registry and born
in Iowa (n=34)
Patients newly diagnosed
with NB (n=141)
32 (% unclear) 97 (100) 35 (% unclear) 34 (100) 141 (100)
nm Stage 1, 8%; 2, 13%; 3, 18%; 4,
50%; 4s, 11%
nm nm Stage 1, 23.4%; 2, 9.2%; 3,
24.1%; 4, 31.9%; 4s, 11.3%
– Birth certificates of age matched
controls randomly selected
from all live births
in the same state
(n=388)
Age- and sex-matched
designated controls
from general practitioner
lists (n=555)
– Live births in British
Columbia Health
Surveillance Registry
1979–1988 (n=419,646)
Review of
radiographs
and re-examination
of patients
Review of birth certificates
and supplemental information
forms
Parental interview,
verification of
information in obstetric
records and general
practitioners’ records
Review of records from
birth defects registry after
linkage with cancer
registry
Patients: review of charts
Controls: data in registry
Results
0 (0) 0 (0) 1 (2.9) 1 (2.9) 6 (4.3)
– 0 (0) 0 (0) – Expected in patient cohort:
1.75
– nm nm – P<0.01
Study Narod et al. [24] Friedman et al. [10] Nishi et al. [26] George et al. [11]
Eur J Pediatr (2009) 168:1081–1090 1085ma patients (two of 119, 1.7%) did not differ significantly
from the proportion of CHD in this control group (seven of
192, 3.6%) (P=0.49). EUROCAT Northern Netherlands
reported 2,526 patients with CHD in 404,790 live births
between January 1981 and January 2006, which corre-
sponds to a prevalence rate of 62.4 per 10,000 (0.62%). The
proportion of CHD in our neuroblastoma cohort was not
significantly higher than the proportion of CHD reported by
EUROCAT (P=0.17).
Reviewofthemedicalchartsofthe14survivingpatientsin
whom echocardiography could not be obtained (n=12) or
echocardiography was inaccurate (n=2), did not reveal
evidence of CHD. Medical records were still available of
176 of 185 deceased patients (95.1%). Review of these
records showed CHD in one patient (coarctation of the aorta
and bicuspid aortic valve). In the remaining 175 patients no
evidence of CHD was observed. When we considered all
survivors and non-survivors together, echocardiography or
medical records were available in 309 patients (133 survivors
and 176 non-survivors). If we assumed that all patients
without evidence of CHD have normal hearts, three of 309
patients (1.0%, 95% CI 0.20–2.81) had CHD.
Table 2 (continued)
Study Narod et al. [24] Friedman et al.
[10]
Nishi et al. [26] George et al. [11]
Country and time period England, Scotland, Wales,
1971–1986
USA, in parts
1965–1994
Japan, 1969–1996 USA, 1990–2000
Design and setting Multicentre (national
cancer registry)
retrospective
cohort study
Single centre
retrospective
patient series
Multicentre
(national cancer registry)
retrospective
cohort study
Single centre
retrospective
cohort study
Patients and methods
NB patients Patients (<15 years)
diagnosed with NB
in registry
(n=1208)
Patients with NB
listed in autopsy
files (n=58)
Patients (<=14 years)
with NB in registry
(n=nm)
Patients newly
diagnosed
with NB
(n=158)
b
N of patients analysed (%) 1208 (100) 58 (100) 323 (>95) 70 (44)
NB stage nm nm nm INSS stage
1–3, 31%;
stage 4, 69%
Control patients –– – Consecutive
patients with acute
lymphoblastic
leukaemia from the
same centre, same
period (n=192)
Method of review of cardiac status Information from
hospitals and family
doctors, postal
questionnaire to
family doctors
(in part of patients)
Review of data in
computerised
autopsy databank
Cancer registry data Retrospective
review of
echocardiographic
reports
Results
N of patients with CHD
(%)
7 (0.6) 2 (3.5) 2 (0.6) 14 (20.0)
N of controls with CHD
(%)
–– – 7 (3.6)
Significance –– – P=0.0001
Menegaux et al. [18] Yanai et al. [29] Chow et al. [5] Munzer et al. [22] Current study
1086 Eur J Pediatr (2009) 168:1081–1090Systematic review of literature, methods and results
To evaluate the existing evidence regarding the prevalence
of CHD in neuroblastoma patients, we searched the
electronic databases of PubMed (January 1966 to Decem-
ber 2007) and Embase (1980 to December 2007), as well as
references of eligible papers. The main search terms were
neuroblastoma and congenital heart defects. We collected
all studies of neuroblastoma patient series that reported on
the proportion of CHD. The study cohort should at least
include 20 neuroblastoma patients. The number of 20 was
arbitrarily chosen, as we estimated that smaller cohorts or
case series might introduce uncontrollable bias. Information
about study design, study group and results were abstracted
by two independent reviewers (KVE and JHM). The two
independent reviewers also critically appraised internal and
external validity of each study. The validity assessment was
based on the guidelines proposed by Hayden et al. [12].
Details about the search strategy and validity assessment
can be obtained from the authors.
Table 2 (continued)
Menegaux et al. [18] Yanai et al. [29] Chow et al. [5] Munzer et al. [22] Current study
USA/Canada,
1992–1994
Japan, 1990–2002 USA, 1980–2004 France, 2003–2004 Netherlands,
1966–2006
Multicentre
(139 hospitals)
retrospective
cohort study
Two-centre retrospective
patient series
Multicentre (national
cancer registry)
retrospective
cohort study
Multi-centre
(National Registry
of childhood
solid tumours)
retrospective
cohort study
Single centre
retrospective/
prospective
cohort study
Patients and methods
Patients (<19 years)
newly diagnosed
with NB (n=741)
Patients newly
diagnosed with
NB (n=nm)
c
Patients (<20 yrs)
newly diagnosed
with NB and born
in Washington
(n=240)
Patients (<15 years)
newly diagnosed
with NB, surviving
and not terminally
ill (n=235)
Patients newly diagnosed
with NB, alive at time
of study (n=133)
538 (73) 156 (% unclear) 240 (100) 191 (75) 119 (89.5)
nm nm Localised, 12.9%; regional,
20%; distant metastatic,
40.8%; unspecified, 26.3%
nm INSS stage I–3, 62.2%;
stage 4, 37.8%
Age matched controls
selected through
a random digit
dialling method
(n=504)
– Birth certificates
of age matched
controls from
the same area
(n=2,400)
Age and sex
matched controls
selected through
a random digit
dialing method
(n=1,681)
Consecutive patients
with acute lymphoblastic
leukaemia ontrol
group presented by
George et al.
[11]( n=192)
Standardised telephone
interview
with mother
Review of charts Review of birth
certificates and hospital
discharge records
database after linkage
with cancer registry
Standardised
telephone
interview
with mother
Prospective
echocardiography
in 102 patients;
review of
echocardiography
images in
17 patients
Results
15 (2.0) 4 (2.6) 5 (2.1) 0 (0) 2 (1.68)
3 (0.6) – 9 (0.4) 5 (0.3) 7 (3.6)
Odds ratio 4.27
(95% CI 1.22–15.0)
d
– Odds ratio 5.84
(95% CI 1.93–17.66)
d
Odds ratio 0
d P=0.49
NB neuroblastoma, CHD congenital heart defects, nm not mentioned
aNeuroblastoma was detected incidentally at autopsy in all patients with CHD
bIn six patients neuroblastoma was detected incidentally in three cases during evaluation of CHD
Eur J Pediatr (2009) 168:1081–1090 1087The literature search identified 515 unique articles.
Reasons for exclusion are detailed in Fig. 2. Seventeen
articles were eligible for our review. Table 2 presents
descriptive characteristics and results of all studies, including
the present one. The studies differed largely in terms of
patient characteristics and methodology. The study of George
et al. [11] was the only study in which patients had
undergone echocardiography; the authors reviewed the
echocardiographic images that had been recorded previously.
In all other articles, it was not mentioned which cardiac
assessment was used. The reported prevalence rates of CHD
in neuroblastoma patients ranged from 0 to 20%, although
the majority of the studies (14 out of 17) found a prevalence
of less than 3.6% [2, 5, 10, 16, 18–26, 29]. In the
echocardiographic review study, the prevalence was 20%.
Figure 3 is an illustration of the prevalence rates of CHD
with 95% confidence interval of proportion as calculated by
us. A statistically higher prevalence of CHD in patients as
compared to controls was present in six of eight studies that
included a control group [5, 6, 9, 11, 16, 18]. However, all
studies lacked information on different items of validity.
In conclusion, several studies have evaluated the
prevalence of CHD in neuroblastoma patients, with little
information on validity. Echocardiography had been per-
formed in only one study. The majority of the studies
reported a prevalence of less than 3.6%, however, a
prevalence of 20% was found in the echocardiographic
review study.
Discussion
In this single centre cohort of consecutive neuroblastoma
patients, the prevalence of CHD was 1.7%, which was not
significantly different from two control groups [11].
The prevalence of CHD found in our study was much
lower than the prevalence of 20% reported in the only other
study in which echocardiography was used for detection of
CHD, the study by George et al. [11]. Both studies have
some limitations, however. In both studies it was not
possible to evaluate the patients who died before echocar-
diographic assessment and this might have led to under-
estimation of prevalence of CHD in both studies. George et
al. [11] did not perform echocardiography in all surviving
neuroblastoma patients. Instead, the authors retrospectively
analysed echocardiographic records and echocardiography
was available in only 43% of neuroblastoma patients. This
might have led to an over-estimation of the prevalence of
CHD, since patients with CHD are more likely to have had
echocardiography. In our study, we prospectively per-
formed echocardiography in almost all eligible patients,
regardless of symptoms or need for specific treatment.
Another explanation for the difference in outcome of our
study and the study by George et al. might be that patients
in our study were older at time of echocardiography.
Because some types of CHD can resolve spontaneously
over time, such as spontaneous closure of septal defects
[27], CHD might have been missed in our study. One
patient in our study indeed had a VSD that had spontane-
ously closed. However, most CHD do not disappear over
time and would have been detected if present. An additional
explanation for the high prevalence rate found by George et
al. as compared to our study could be referral bias in their
tertiary care centre study [11]. An important potential
source of bias that may have led to overestimation of
CHD in the study of George et al. as well as in other studies
and case reports, is surveillance bias: patients with
neuroblastoma are investigated thoroughly, during which
(asymptomatic) CHD might be detected. Likewise, neuro-
blastoma can be detected during workup of CHD patients.
Fig. 3 Overview of prevalence
rates (%) of CHD in the selected
studies with 95% Confidence
Interval. The prevalence rate in
the control group (George et al.)
is also shown
1088 Eur J Pediatr (2009) 168:1081–1090It is well known that lower stage neuroblastoma can regress
spontaneously over time and therefore these neuroblastoma
might never have come into clinical attention without the
thorough investigations after detection of CHD. This may
artificially increase the difference between prevalence of
CHD in neuroblastoma patients and controls. Indeed, in the
study of George et al. [11] neuroblastoma was detected
during workup for CHD in three patients.
George et al. found a relatively high proportion of
patients with neural crest-derived CHD. Five of 14 (36%)
patients with CHD had neural crest-derived CHD, which is
more than expected when considering the normal distribu-
tion of CHD [13]. This seems in favour of a possible
association between the two conditions, with its source in
the common neural crest origin. However, numbers were
very small in the study of George et al.
The 16 other studies on CHD in neuroblastoma patients
reviewed here, showed prevalence rates much lower than the
20% reported by George et al. In these studies it was not
mentioned how patients were evaluated for the presence of
CHD, but itis unlikelythatthe majority of patients underwent
echocardiography or other imaging techniques. CHD might
thus have been missed. In all of these studies information was
lacking on other items of validity as well. The validity of a
study addresses the issue of whether the researcher actually
measureswhatissaidtobemeasured.Itconcernstheextentto
which the results of a study can be interpreted adequately and
the extent to which we can trust these results. A lack of
information on validity items might lead to invalid results; the
studies reviewed here might have been subject to various
types of bias. For example, a well-defined definition of CHD
was not given in the studies, which led to difficulties in
interpretation of what exactly had been considered as CHD.
The use of a non-representative sample of patients from the
original study group may have led to either over- or under-
estimation of the true prevalence of CHD, depending on
whether patients with a higher or a lower risk profile were
selected for the study. In addition, cancer registries, birth
certificates and medical charts might not contain all medical
information and therefore CHD could be under-reported. In
studies were data from these registries served as control data,
the significance of a higher prevalence of CHD in neuroblas-
toma patients might have been overestimated [7, 9, 15]. In
studies based on parental interviews, recall bias may have led
to overestimation of CHD in neuroblastoma patients. In
addition, studies in tertiary care centres might have been
subject to referral bias.
Non-accuracy of the control group can be a source of
bias as well. We used the consecutive ALL cohort
presented by George et al. as a control group [11]. We
chose this control group because all consecutive children in
this cohort had undergone echocardiography, like the
patients in our study group. A concern might be that the
control group comprises patients from another country. We
therefore also compared the prevalence of CHD in our
cohort to data from EUROCAT Northern Netherlands, with
non-significant results. As mentioned above, use of data
from a health registry for comparison may lead to bias as
well. However, because data in health registries might be
prone to under-representation of anomalies in the general
population [7, 9, 15], this would imply that the significance
of the difference is even less than described.
In conclusion, although several studies have addressed
the prevalence of CHD in neuroblastoma patients, only the
present study and the study of George et al. [11] used
adequate methodology and had reasonable validity to
determine the prevalence of CHD in these patients.
However, the results differed largely between these two
studies. The difference may in part be explained by
differences in methodology and patient characteristics, but
may be due to chance as well. Therefore, the association
between neuroblastoma and CHD remains unclear. To
confirm or reject the true existence of such an association,
further research in a large and complete cohort of
neuroblastoma patients is needed. Our study and systematic
review have shown, however, that clear evidence of an
association between neuroblastoma and CHD is lacking.
Standard cardiac screening in all patients with neuroblasto-
ma is therefore not supported by current evidence.
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